Federated Hermes Inc. Has $19.15 Million Holdings in Halozyme Therapeutics, Inc. $HALO

Federated Hermes Inc. boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 368,066 shares of the biopharmaceutical company’s stock after purchasing an additional 8,529 shares during the period. Federated Hermes Inc. owned about 0.30% of Halozyme Therapeutics worth $19,147,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of HALO. Wealth Preservation Advisors LLC acquired a new position in Halozyme Therapeutics during the 1st quarter worth about $32,000. SVB Wealth LLC bought a new position in shares of Halozyme Therapeutics during the first quarter worth about $33,000. Employees Retirement System of Texas bought a new position in shares of Halozyme Therapeutics during the second quarter worth about $34,000. Brooklyn Investment Group lifted its stake in shares of Halozyme Therapeutics by 1,558.1% in the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 670 shares during the period. Finally, Asset Management One Co. Ltd. bought a new stake in Halozyme Therapeutics in the second quarter valued at approximately $98,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Up 1.3%

Shares of NASDAQ HALO opened at $62.65 on Thursday. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. The firm has a market cap of $7.37 billion, a PE ratio of 13.19, a P/E/G ratio of 0.33 and a beta of 0.95. The company’s fifty day simple moving average is $67.49 and its 200 day simple moving average is $64.51. Halozyme Therapeutics, Inc. has a 12-month low of $46.26 and a 12-month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The company had revenue of $354.26 million for the quarter, compared to analysts’ expectations of $339.18 million. During the same quarter in the prior year, the firm earned $1.27 EPS. The business’s revenue was up 22.1% on a year-over-year basis. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on HALO shares. HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a report on Friday, November 28th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 14th. Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday. Finally, Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 6th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $75.10.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 16,569 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $68.92, for a total transaction of $1,141,935.48. Following the completion of the sale, the chief executive officer owned 708,719 shares in the company, valued at $48,844,913.48. The trade was a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Bernadette Connaughton sold 829 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $71.60, for a total value of $59,356.40. Following the transaction, the director directly owned 42,123 shares in the company, valued at $3,016,006.80. The trade was a 1.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 83,625 shares of company stock valued at $5,932,527. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.